Cargando…
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration
BACKGROUND AND OBJECTIVES: Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies is a cancer-related autoimmune disease directed against neural antigens expressed by tumor cells. A putative trigger of the immune tolerance breakdown is genetic alteration of Yo antigens. We aimed to ide...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278124/ https://www.ncbi.nlm.nih.gov/pubmed/35821104 http://dx.doi.org/10.1212/NXI.0000000000200015 |
_version_ | 1784746133458780160 |
---|---|
author | Peter, Elise Treilleux, Isabelle Wucher, Valentin Jougla, Emma Vogrig, Alberto Pissaloux, Daniel Paindavoine, Sandrine Berthet, Justine Picard, Géraldine Rogemond, Véronique Villard, Marine Vincent, Clémentine Tonon, Laurie Viari, Alain Honnorat, Jérôme Dubois, Bertrand Desestret, Virginie |
author_facet | Peter, Elise Treilleux, Isabelle Wucher, Valentin Jougla, Emma Vogrig, Alberto Pissaloux, Daniel Paindavoine, Sandrine Berthet, Justine Picard, Géraldine Rogemond, Véronique Villard, Marine Vincent, Clémentine Tonon, Laurie Viari, Alain Honnorat, Jérôme Dubois, Bertrand Desestret, Virginie |
author_sort | Peter, Elise |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies is a cancer-related autoimmune disease directed against neural antigens expressed by tumor cells. A putative trigger of the immune tolerance breakdown is genetic alteration of Yo antigens. We aimed to identify the tumors' genetic and immune specificities involved in Yo-PCD pathogenesis. METHODS: Using clinicopathologic data, immunofluorescence (IF) imaging, and whole-transcriptome analysis, 22 breast cancers (BCs) associated with Yo-PCD were characterized in terms of oncologic characteristics, genetic alteration of Yo antigens, differential gene expression profiles, and morphofunctional specificities of their in situ antitumor immunity by comparing them with matched control BCs. RESULTS: Yo-PCD BCs were invasive carcinoma of no special type, which early metastasized to lymph nodes. They overexpressed human epidermal growth factor receptor 2 (HER2) but were hormone receptor negative. All Yo-PCD BCs carried at least 1 genetic alteration (variation or gain in copy number) on CDR2L, encoding the main Yo antigen that was found aberrantly overexpressed in Yo-PCD BCs. Analysis of the differentially expressed genes found 615 upregulated and 54 downregulated genes in Yo-PCD BCs compared with HER2-driven control BCs without PCD. Ontology enrichment analysis found significantly upregulated adaptive immune response pathways in Yo-PCD BCs. IF imaging confirmed an intense immune infiltration with an overwhelming predominance of immunoglobulin G–plasma cells. DISCUSSION: These data confirm the role of genetic alterations of Yo antigens in triggering the immune tolerance breakdown but also outline a specific biomolecular profile in Yo-PCD BCs, suggesting a cancer-specific pathogenesis. |
format | Online Article Text |
id | pubmed-9278124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92781242022-08-02 Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration Peter, Elise Treilleux, Isabelle Wucher, Valentin Jougla, Emma Vogrig, Alberto Pissaloux, Daniel Paindavoine, Sandrine Berthet, Justine Picard, Géraldine Rogemond, Véronique Villard, Marine Vincent, Clémentine Tonon, Laurie Viari, Alain Honnorat, Jérôme Dubois, Bertrand Desestret, Virginie Neurol Neuroimmunol Neuroinflamm Research Article BACKGROUND AND OBJECTIVES: Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies is a cancer-related autoimmune disease directed against neural antigens expressed by tumor cells. A putative trigger of the immune tolerance breakdown is genetic alteration of Yo antigens. We aimed to identify the tumors' genetic and immune specificities involved in Yo-PCD pathogenesis. METHODS: Using clinicopathologic data, immunofluorescence (IF) imaging, and whole-transcriptome analysis, 22 breast cancers (BCs) associated with Yo-PCD were characterized in terms of oncologic characteristics, genetic alteration of Yo antigens, differential gene expression profiles, and morphofunctional specificities of their in situ antitumor immunity by comparing them with matched control BCs. RESULTS: Yo-PCD BCs were invasive carcinoma of no special type, which early metastasized to lymph nodes. They overexpressed human epidermal growth factor receptor 2 (HER2) but were hormone receptor negative. All Yo-PCD BCs carried at least 1 genetic alteration (variation or gain in copy number) on CDR2L, encoding the main Yo antigen that was found aberrantly overexpressed in Yo-PCD BCs. Analysis of the differentially expressed genes found 615 upregulated and 54 downregulated genes in Yo-PCD BCs compared with HER2-driven control BCs without PCD. Ontology enrichment analysis found significantly upregulated adaptive immune response pathways in Yo-PCD BCs. IF imaging confirmed an intense immune infiltration with an overwhelming predominance of immunoglobulin G–plasma cells. DISCUSSION: These data confirm the role of genetic alterations of Yo antigens in triggering the immune tolerance breakdown but also outline a specific biomolecular profile in Yo-PCD BCs, suggesting a cancer-specific pathogenesis. Lippincott Williams & Wilkins 2022-07-12 /pmc/articles/PMC9278124/ /pubmed/35821104 http://dx.doi.org/10.1212/NXI.0000000000200015 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Research Article Peter, Elise Treilleux, Isabelle Wucher, Valentin Jougla, Emma Vogrig, Alberto Pissaloux, Daniel Paindavoine, Sandrine Berthet, Justine Picard, Géraldine Rogemond, Véronique Villard, Marine Vincent, Clémentine Tonon, Laurie Viari, Alain Honnorat, Jérôme Dubois, Bertrand Desestret, Virginie Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title | Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title_full | Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title_fullStr | Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title_full_unstemmed | Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title_short | Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo–Associated Paraneoplastic Cerebellar Degeneration |
title_sort | immune and genetic signatures of breast carcinomas triggering anti-yo–associated paraneoplastic cerebellar degeneration |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278124/ https://www.ncbi.nlm.nih.gov/pubmed/35821104 http://dx.doi.org/10.1212/NXI.0000000000200015 |
work_keys_str_mv | AT peterelise immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT treilleuxisabelle immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT wuchervalentin immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT jouglaemma immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT vogrigalberto immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT pissalouxdaniel immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT paindavoinesandrine immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT berthetjustine immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT picardgeraldine immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT rogemondveronique immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT villardmarine immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT vincentclementine immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT tononlaurie immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT viarialain immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT honnoratjerome immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT duboisbertrand immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration AT desestretvirginie immuneandgeneticsignaturesofbreastcarcinomastriggeringantiyoassociatedparaneoplasticcerebellardegeneration |